Lysozyme (Muramidase), Plasma
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Confirming marked increases in the granulocyte or monocyte pools as in granulocytic or monocytic leukemias, myeloproliferative disorders, and malignant histiocytosis
Following the course of therapy in cases of chronic granulocytic or chronic monocytic leukemias
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Lysozyme (Muramidase), P
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Collection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 2 mL
Forms: If not ordering electronically, please submit a Hematopathology/Molecular Oncology Request Form (Supply T241) with the specimen.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Mild OK; Gross OK
Mild OK; Gross OK
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Plasma EDTA||Frozen||30 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Lysozyme is a bacteriolytic enzyme that is found in some hematopoietic cells. It is primarily present in granulocytes, monocytes, and histiocytes. The enzyme is present in only minute amounts in lymphocytes; and is not present in myeloblasts, eosinophils, and basophils.
Lysozyme in the plasma comes chiefly from the degradation of granulocytes and monocytes and its concentration reflects the turnover of these cells. Increases are seen in benign (eg, infection, inflammation) and malignant processes(eg, some leukemias). Plasma lysozyme is elevated in patients with acute or chronic granulocytic or monocytic leukemias and falls with successful treatment. Conversely, patients with lymphocytic leukemia may have depressed plasma lysozyme levels.
Patients with renal disorders (including rejection of transplanted kidneys) or Crohn’s disease (regional enteritis) also tend to have elevated levels of plasma lysozyme.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
Levels >200 mcg/mL may be seen in acute nonlymphocytic leukemia (M2, M4, M5) or chronic granulocytic leukemias.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Increased levels may be seen in nonmalignant disorders including infections, Crohn’s disease, kidney transplant rejection, and other renal disorders.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
Catovsky D, Galton DA, Griffin C: The significance of lysozyme estimations in acute myeloid and chronic monocytic leukaemia. Brit J Haematol 1971;21:565-580
Method Description Describes how the test is performed and provides a method-specific reference
The term "lysozyme" is derived from the ability of this enzyme to dissolve the walls of certain bacteria, including Micrococcus lysodeikticus. This organism is suspended in buffer, and the plasma sample is added. The resulting decrease in turbidity is measured spectrophotometrically. The rate of clearing is a reflection of the concentration of the enzyme.(Litwack G: Photometric determination of lysozyme activity. Proc Soc Exp Biol Med 1955;89:401-403)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|
|MUR||Lysozyme (Muramidase), P||2589-0|